Baichuan Intelligence Completes RMB 5B Series A Funding, Proprietary General Medical-Enhanced Large Model Outperforms GPT-4 in Multiple Benchmarks

It is reported that BAICHUAN AI has recently completed its Series A financing, raising a total of RMB 5 billion, and will initiate its Series B round at a valuation of RMB 20 billion. The Series A investors include leading tech giants and market-oriented investment institutions such as Alibaba, Xiaomi, Tencent, Asia Investment Capital, and CICC, as well as state-backed industrial investment funds including the Beijing Artificial Intelligence Industry Investment Fund, the Shanghai Artificial Intelligence Industry Investment Fund, and Shenzhen Capital Group (SCGC).

BAICHUAN AI has consistently adhered to a dual-drive development strategy of “super models + super applications.” To date, it has released 12 large language models and launched its first AI assistant, Bai Xiaoying, in May this year.

BAICHUAN AI has long regarded healthcare as the “crown jewel of large language models” and the optimal scenario for building super-apps. As the only leading large-model company in China focused exclusively on healthcare, BAICHUAN AI has achieved phased progress in both AI healthcare technology and applications. Its self-developed general-purpose medically enhanced large model has surpassed GPT-4 in multiple authoritative benchmarks, and the company made its first public demonstration of an AI healthcare application—AI Health Advisor—at the World Artificial Intelligence Conference (WAIC) held in early July.